Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Teresa Zielli"'
Autor:
Marco Maruzzo, Elena Verzoni, Maria Giuseppa Vitale, Michele Dionese, Sebastiano Buti, Luca Galli, Andrea Zivi, Sara Watutantrige-Fernando, Teresa Zielli, Elisa Zanardi, Roberto Sabbatini, Umberto Basso, Vittorina Zagonel, Giuseppe Procopio
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThyroid hormone impairment, represented as an alteration in levels of thyroid hormones and a lower fT3/fT4 ratio, has been correlated with a worse prognosis for both cancer and non-cancer patients. The role of baseline thyroid function in p
Externí odkaz:
https://doaj.org/article/9a3e4a93738845bf87bc0203274f79b2
Autor:
Sebastiano Buti, Fabiana Perrone, Teresa Zielli, Giulia Mazzaschi, Chiara Casartelli, Alessandro Leonetti, Gianluca Milanese, Mario Silva, Roberta Eufrasia Ledda, Antonino Musolino, Francesca Pucci, Melissa Bersanelli, Marcello Tiseo
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 15 (2021)
Background: Coronavirus disease (COVID-19), an acute respiratory syndrome caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has rapidly spread worldwide, significantly affecting the outcome of a highly vulnerable group suc
Externí odkaz:
https://doaj.org/article/444b4ca858de4410bb7acae0b38de710
Autor:
Anna Maria Militello, Teresa Zielli, Daniela Boggiani, Maria Michiara, Nadia Naldi, Beatrice Bortesi, Paola Zanelli, Vera Uliana, Sara Giuliotti, Antonino Musolino
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Sensitivity to endocrine therapy of patients with estrogen receptor (ER)-positive metastatic breast cancer and germline BRCA1/2 mutations is not yet fully elucidated. Furthermore, the registration trials of CDK 4/6 inhibitors in combination with endo
Externí odkaz:
https://doaj.org/article/400b5d8ca9a14a24b36de58980dd7704
Publikováno v:
Tumori Journal. 106:NP79-NP83
Background: Papillary renal cell carcinoma (pRCC) represents the second most common histologic subtype of renal cell carcinoma and comprises 2 subtypes. Prognosis for type 2 is associated with poor clinical outcome. Current guidelines are based on ph
Autor:
Francesca Pucci, Sebastiano Buti, Fabiana Perrone, Teresa Zielli, Marcello Tiseo, Melissa Bersanelli, Alessandro Leonetti, Gianluca Milanese, Antonino Musolino, Roberta Eufrasia Ledda, Mario Silva, Giulia Mazzaschi, Chiara Casartelli
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 15 (2021)
Clinical Medicine Insights. Oncology
Clinical Medicine Insights. Oncology
Background: Coronavirus disease (COVID-19), an acute respiratory syndrome caused by a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2), has rapidly spread worldwide, significantly affecting the outcome of a highly vulnerable group suc
Autor:
Francesca Bozzetti, Roberta Minari, Irene Florindo, Girolamo Crisi, Giovanni Ceccon, Marcello Tiseo, Francesco Facchinetti, Teresa Zielli
Publikováno v:
Tumori Journal. 104:NP29-NP33
Introduction: Treatment paradigms for EGFR-mutated non-small cell lung cancer (NSCLC) have successfully evolved since the introduction of osimertinib. The detection of EGFR T790M mutation in plasma or tumor samples obtained at disease progression to
Autor:
Pier Giorgio Petronini, Alessandro Leonetti, Costanza Lagrasta, Roberta Minari, Lorena Bottarelli, Teresa Zielli, Luigi Ventura, Marcello Tiseo, Letizia Gnetti, Silvia La Monica, Roberta Alfieri
Publikováno v:
Anti-cancer drugs. 32(7)
Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) used both as the first-line treatment of EGFR-mutated non-small cell lung cancer patients and in second-line after T790M-positive disease progress
Autor:
Monia Sisi, Marcello Tiseo, Francesco Facchinetti, Teresa Zielli, Andrea Ardizzoni, Francesco Gelsomino
Novel treatment strategies incorporating PD-1/PD-L1 inhibitors in the first-line setting of advanced non-small-cell lung cancer (NSCLC) provided relevant improvements in survival outcomes. Among NSCLC patients with PD-L1 tumor proportion score ≥50%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e1bcedaf2b13744d04d63c2a3926eb9
http://hdl.handle.net/11585/851649
http://hdl.handle.net/11585/851649
Autor:
Fabiana Pratticò, Paola Bordi, Melissa Bersanelli, Fabiana Perrone, Elena Rapacchi, Marcello Tiseo, Teresa Zielli, Alberto Clemente, Alessandro Leonetti, Michele Tognetto, Sebastiano Buti, Sara Elena Rebuzzi, Chiara Casartelli, Diana Giannarelli, Roberta Camisa
Publikováno v:
Immunotherapy
Aim: Evaluating the incidence and course of COVID-19 in cancer patients treated with immunotherapy. Patients & methods: We reported the influenza-like illness events with diagnosis of COVID-19 within the patient cohort enrolled in the prospective obs
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2020, 132, pp.122-124. ⟨10.1016/j.ejca.2020.04.004⟩
European Journal of Cancer, 2020, 132, pp.122-124. ⟨10.1016/j.ejca.2020.04.004⟩
European Journal of Cancer, Elsevier, 2020, 132, pp.122-124. ⟨10.1016/j.ejca.2020.04.004⟩
European Journal of Cancer, 2020, 132, pp.122-124. ⟨10.1016/j.ejca.2020.04.004⟩
International audience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::802616e08c63e751024256a396337e88
https://www.hal.inserm.fr/inserm-02565846/document
https://www.hal.inserm.fr/inserm-02565846/document